Paul Chapple

Prof. Paul Chapple

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2005 in Nature Genetics
Verified
Journal Article
Closed access
ARAlison J Ross
Alison J Ross
HMHelen May-Simera
Helen May-Simera
EEErica R Eichers
Erica R Eichers
MKMasatake Kai
Masatake Kai
JHJosephine Hill
Josephine Hill
PBPhilip L Beales
Philip L Beales

16 January 2005 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LMLou Metherell
Lou Metherell
PCPaul Chapple
Paul Chapple
SCSadani Cooray
Sadani Cooray
ADAlessia David
Alessia David
CBChristian Becker
Christian Becker
ACAdrian J L Clark
Adrian J L Clark

1 April 2005 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
HMHugo F. Mendes
Hugo F. Mendes
JSJacqueline van der Spuy
Jacqueline van der Spuy
PCPaul Chapple
Paul Chapple
MCMichael E. Cheetham
Michael E. Cheetham

1 June 2008 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
CLChrysanthia A. Leontiou
Chrysanthia A. Leontiou
MGMaria Gueorguiev
Maria Gueorguiev
JSJacqueline van der Spuy
Jacqueline van der Spuy
RQRichard Quinton
Richard Quinton
FLFrancesca Lolli
Francesca Lolli
MKMárta Korbonits
Márta Korbonits
Context: Mutations have been identified in the aryl hydrocarbon receptor-interacting protein (AIP) gene in familial isolated pituitary adenomas (FIPA). It is not clear, however, how this molecular chaperone is involved in tumorigenesis. Objective: AIP sequence changes and expression were studied in FIPA and sporadic adenomas. The function of normal and mutated AIP molecules was studied on cell proliferation and protein-protein interaction. Cellular and ultrastructural AIP localization was determined in pituitary cells. Patients: Twenty-six FIPA kindreds and 85 sporadic pituitary adenoma patients were included in the study. Results: Nine families harbored AIP mutations. Overexpression of wild-type AIP in TIG3 and HEK293 human fibroblast and GH3 pituitary cell lines dramatically reduced cell proliferation, whereas mutant AIP lost this ability. All the mutations led to a disruption of the protein-protein interaction between AIP and phosphodiesterase-4A5. In normal pituitary, AIP colocalizes exclusively with GH and prolactin, and it is found in association with the secretory vesicle, as shown by double-immunofluorescence and electron microscopy staining. In sporadic pituitary adenomas, however, AIP is expressed in all tumor types. In addition, whereas AIP is expressed in the secretory vesicle in GH-secreting tumors, similar to normal GH-secreting cells, in lactotroph, corticotroph, and nonfunctioning adenomas, it is localized to the cytoplasm and not in the secretory vesicles. Conclusions: Our functional evaluation of AIP mutations is consistent with a tumor-suppressor role for AIP and its involvement in familial acromegaly. The abnormal expression and subcellular localization of AIP in sporadic pituitary adenomas indicate deranged regulation of this protein during tumorigenesis.

27 May 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
EMEirini Meimaridou
Eirini Meimaridou
JKJulia Kowalczyk
Julia Kowalczyk
LGLeonardo Guasti
Leonardo Guasti
CHClaire R Hughes
Claire R Hughes
FWFlorian Wagner
Florian Wagner
LMLou Metherell
Lou Metherell
Adrian Clark and colleagues report mutations in the NNT gene encoding nicotinamide nucleotide transhydrogenase in familial glucocorticoid deficiency (FGD). Using targeted exome sequencing, we identified mutations in NNT, an antioxidant defense gene, in individuals with familial glucocorticoid deficiency. In mice with Nnt loss, higher levels of adrenocortical cell apoptosis and impaired glucocorticoid production were observed. NNT knockdown in a human adrenocortical cell line resulted in impaired redox potential and increased reactive oxygen species (ROS) levels. Our results suggest that NNT may have a role in ROS detoxification in human adrenal glands.

14 April 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LCLi Chan
Li Chan
TWTom R. Webb
Tom R. Webb
TCTeng-Teng Chung
Teng-Teng Chung
EMEirini Meimaridou
Eirini Meimaridou
SCSadani N. Cooray
Sadani N. Cooray
ACAdrian J. L. Clark
Adrian J. L. Clark
The melanocortin receptor (MCR) family consists of 5 G protein-coupled receptors (MC1R–MC5R) with diverse physiologic roles. MC2R is a critical component of the hypothalamic–pituitary–adrenal axis, whereas MC3R and MC4R have an essential role in energy homeostasis. Mutations in MC4R are the single most common cause of monogenic obesity. Investigating the way in which these receptors signal and traffic to the cell membrane is vital in understanding disease processes related to MCR dysfunction. MRAP is an MC2R accessory protein, responsible for adrenal MC2R trafficking and function. Here we identify MRAP2 as a unique homologue of MRAP, expressed in brain and the adrenal gland. We report that MRAP and MRAP2 can interact with all 5 MCRs. This interaction results in MC2R surface expression and signaling. In contrast, MRAP and MRAP2 can reduce MC1R, MC3R, MC4R, and MC5R responsiveness to [Nle4,D-Phe7]alpha-melanocyte-stimulating hormone (NDP-MSH). Collectively, our data identify MRAP and MRAP2 as unique bidirectional regulators of the MCR family.